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Cryopyrin-associated periodic syndromes (CAPS)
are caused by aberrant interleukin-1b (IL-1b) produc-
tion induced by mutations in the NLRP3 protein in
humans, but the mechanisms involved remain poorly
understood. Using a mouse model, we show a role
for the indigenous microbiota and mast cells (MCs)
in skin disease associated with mutant Nlrp3 protein.
Unlike normal cells, MCs expressing mutant Nlrp3
produced IL-1b in response to lipopolysaccharide
or tumor necrosis factor-a (TNF-a). In neonatal
mice, the microbiota induced TNF-a and IL-1b and
promoted skin disease. MC deficiency greatly
reduced disease in Nlrp3 mutant mice, and reconsti-
tution of MC-deficient mice with mutant MCs
restored skin disease, which required the expression
of IL-1b in MCs. Surprisingly, neutralization of TNF-a
abrogated IL-1b production and skin disease in
neonatal Nlrp3 mutant mice, but not in affected adult
mice. Thus, the microbiota and MCs initiate cellular
events leading to dysregulated IL-1b production
and skin inflammation in neonatal mice with the
CAPS-associated Nlrp3 mutation.
INTRODUCTION
The innate immune system is activated through the engagement
of host soluble factors and germline-encoded pattern-recogni-
tion receptors (PRRs) by microbial moieties or endogenous
molecules generated in the setting of infection or cellular injury
(Chen and Nun˜ez, 2010; Kawai and Akira, 2010). In response
to infection, PRR activation initiates signal-transduction path-
ways that ultimately culminate in host defense responses that
eliminate microbial invasion. A major inflammatory pathway
is the inflammasome, a multiprotein platform that activates
the protease caspase-1 (Franchi et al., 2009a; Schroder and
Tschopp, 2010). Once activated, caspase-1 proteolyticallyprocesses pro-interleukin-1b (IL-1b) and pro-IL-18, which is
important for secretion of the biologically active forms of these
cytokines (Chen and Nun˜ez, 2010). To date, several inflamma-
somes have been described, of which three, the NLRP1,
NLRP3, and NLRC4 inflammasomes, contain a PRR that
belongs to the intracellular Nod-like receptor (NLR) family. Acti-
vation of the NLRP3 inflammasome is mediated by two signals.
The first signal, referred to as priming, is the nuclear-factor-kB-
dependent transcription of pro-IL-1b and NLRP3 through the
stimulation of PRRs by various Toll-like receptor (TLR) agonists,
including lipopolysaccharide (LPS), or certain cytokines such as
tumor necrosis factor-a (TNF-a) or IL-1b (Bauernfeind et al.,
2009; Franchi et al., 2009b). The second signal activates
NLRP3 and is induced by ATP, certain bacterial toxins, or
a variety of crystalline and particulate matter, including urate
crystals, asbestos fibers, silica, and aluminum salts (Franchi
et al., 2010). In response to activating stimuli, NLRP3 recruits
the adaptor protein ASC (apoptosis-associated speck-like
protein containing a caspase recruitment and activation domain)
and forms an inflammasome that drives caspase-1 activation
(Franchi et al., 2009c).
The importance of the NLRP3 inflammasome is underscored
by the observation that missense mutations in the NLRP3 gene
are responsible for a spectrum of autoinflammatory syndromes
(Aksentijevich et al., 2002; Dowds et al., 2004; Hoffman et al.,
2001). These diseases, collectively referred to as cryopyrin-
associated periodic syndromes (CAPS), are rare monogenic
inherited disorders that are characterized by episodes of fever,
urticarial-like skin rash, and other more variable inflammatory
manifestations, in the absence of autoimmunity or infection
(Aksentijevich et al., 2007; Neven et al., 2004). CAPS include
familial cold autoinflammatory syndrome (FCAS [MIM 120100]),
Muckle-Wells syndrome (MWS [MIM 191900]), and neonatal-
onset multisystem inflammatory disease (NOMID [MIM
607115]). AlthoughCAPS are considered distinct clinical entities,
they represent a continuum in disease severity; FACS patients
are the least affected, MWS patients are in the middle, and
NOMID is the most severe form of disease, causing neurological
deficits and deforming arthritis (Neven et al., 2004). TheseCAPS-
associated missense NLRP3 mutations result in enhanced
activation of caspase-1 and secretion of IL-1b by causingImmunity 37, 85–95, July 27, 2012 ª2012 Elsevier Inc. 85
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MCs and Skin Inflammation Driven by Nlrp3 Mutationconstitutive activation of the NLRP3 inflammasome (Agostini
et al., 2004). Notably, treatment of CAPS patients with an IL-1
receptor antagonist or IL-1b-blocking antibody resolves most
inflammatory signs and symptoms in CAPS, resulting in life-
altering outcomes (Hoffman et al., 2004; Hoffman et al., 2008;
Lachmann et al., 2009). Although CAPS are typically dominantly
inherited disorders and exhibit high penetrance, there is
evidence that environmental factors may play a role in triggering
disease. For example, FCAS inflammatory episodes are often
induced by systemic exposure to cold, MWS attacks can be
induced by several triggers, and NOMID occurs at birth or in
early infancy, but the environmental stimuli that induce disease
onset remain unknown.
Two groups have recently generated gene-targeted mice
harboring Nlrp3 mutations that mimic the amino-acid substitu-
tions found in CAPS (Brydges et al., 2009; Meng et al., 2009).
Brydges et al. generated two disease-associated Nlrp3
mouse strains; one line expressed A350V, corresponding to
human A352V associated with MWS, and another line ex-
pressed L351P, corresponding to the FCAS-associated L353P
mutation (Brydges et al., 2009). Practically all mice from the
latter Nlrp3 mutant strains die within 2 weeks after birth due
to severe systemic inflammation (Brydges et al., 2009). In
contrast, Meng et al. generated Nlrp3 mutant mice that ex-
pressed Nlrp3R258W, corresponding to the MWS-associated
R260W NLRP3 mutation (Meng et al., 2009). Heterozygous
Nlrp3R258W mice exhibited delayed growth, reduced body
weight, and increased mortality, but the great majority of
Nlrp3R258W mice survived after weaning (Meng et al., 2009).
Notably, Nlrp3 mutant mice from both groups developed
dermatitis rich in neutrophils, which histologically resembles
that observed in human CAPS (Brydges et al., 2009; Meng
et al., 2009). Consistent with constitutive activation of the in-
flammasome, priming of macrophages from Nlrp3 mutant
mice with TLR agonists alone induced caspase-1 activation
and robust IL-1b production (Brydges et al., 2009; Meng
et al., 2009). Furthermore, genetic deletion or neutralization of
IL-1 signaling induced marked improvement of disease,
whereas ablation of Asc abrogated perinatal mortality and cuta-
neous disease in Nlrp3 mutant mice (Brydges et al., 2009; Meng
et al., 2009).
Several hematopoietic cells, including macrophages,
dendritic cells, neutrophils, and mast cells (MCs), can produce
IL-1b in response to microbial and endogenous stimuli (Franchi
et al., 2007; Ghiringhelli et al., 2009; Nakamura et al., 2009).
Surprisingly, most of the IL-1b-positive cells in the skin lesions
of CAPS patients are MCs (Nakamura et al., 2009). Furthermore,
MCs can produce IL-1b via the Nlrp3 inflammasome (Nakamura
et al., 2009). However, the role of MCs in skin disease associated
with Nlrp3 mutations has not been investigated. Additionally, the
environmental and host factors that initiate IL-1b-driven skin
inflammation in the context of disease-associated Nlrp3 muta-
tions remain elusive. In the present study, we show that MCs
play a critical role in triggering disease in neonatal Nlrp3 mutant
mice. Production of TNF-a and IL-1b by MCs was important for
IL-1b-driven skin disease in Nlrp3 mutant mice. Furthermore, we
provide evidence that the indigenous microbiota promote TNF-a
and IL-1b production and contribute to skin disease in Nlrp3
mutant mice.86 Immunity 37, 85–95, July 27, 2012 ª2012 Elsevier Inc.RESULTS
Cutaneous Inflammation Induced by Nlrp3R258W
Mutation Requires MCs
Previous studies showed that the majority of IL-1b-producing
cells in the dermis of skin lesions from CAPS patients are
MCs (Nakamura et al., 2009). Therefore, we tested whether
MCs play a role in skin inflammation of mice expressing an
R258W mutation in Nlrp3. To assess this, we crossed hetero-
zygous Nlrp3R258W mice with C57BL6-KitW-sh/W-sh mice to
generate littermate mice expressing the Nlrp3R258W mutation in
the normal and MC-deficient background. Within the first week
after birth, Nlrp3R258W and wild-type littermates were indistin-
guishable. However, beginning 7 days after birth, Nlrp3R258W
mice raised under pathogen-free conditions displayed impaired
weight gain (Figure 1A). In contrast, the increase in body weight
was comparable in Nlrp3R258WKitW-sh/W-sh and their control B6-
KitW-sh/W-sh littermates (Figure 1A). Notably, neonatal Nlrp3R258W
mice developed elevated amounts of IL-1b in serum and
splenomegaly, which was greatly attenuated or abolished in
their Nlrp3R258WKitW-sh/W-sh littermates (Figures 1B and 1C). In
addition, 100% of the Nlrp3R258W mice developed skin disease
in the posterior collar area and perianal region by 2 weeks
after birth (Figures 1D and 1E; Figure S1 available online).
Furthermore, the incidence and severity of skin disease in
Nlrp3R258WKitW-sh/W-sh mice was greatly reduced compared to
their Nlrp3R258W littermates (Figures 1D and 1E; Figure S1).
Consistent with these findings, the skin of Nlrp3R258W mice
showed hyperkeratosis and marked neutrophil-rich infiltrate,
which were absent or highly reduced in the same skin area of
Nlrp3R258WKitW-sh/W-sh mice (Figure 1F). As expected, abundant
MCs were observed in the skin of Nlrp3R258W mice, but not in
neonatal Nlrp3R258WKitW-sh/W-sh mice (Figure 1G). Immunohisto-
chemistry revealed that cells labeled with avidin (a marker of
MCs) produced IL-1b in the dermis of neonatal Nlrp3R258W
mice, but not in their Nlrp3R258WKitW-sh/W-sh or wild-type litter-
mates (Figure 1G). These results indicate that MCs play a critical
role in the development of cutaneous inflammation induced by
the disease-associated Nlrp3R258W mutation.
Priming with LPS or TNF-a Is Sufficient to Induce
Caspase-1 Activation and IL-1b Secretion in MCs
Expressing the Nlrp3R258W Mutation
To begin to understand howMCs contribute to inflammatory skin
disease, we prepared bone marrow-derived MCs (BMCMCs)
from wild-type and Nlrp3R258W mice and determined their ability
to produce IL-1b through the Nlrp3 inflammasome. BMCMCs
from Nlrp3R258W and wild-type mice exhibited comparable
morphology, expression of CD117, and the ability to release
b-hexosaminidase in response to several stimuli (Figure S2). As
previously reported (Nakamura et al., 2009), IL-1b secretion by
MCs from wild-type mice required both priming with LPS and
stimulation with ATP or the RNA-like molecule R837 (Figure 2A).
In contrast, stimulation with LPS was sufficient to induce robust
IL-1b secretion in MCs from Nlrp3R258W mice (Figure 2A). This
differential response was specific in that MCs from wild-type
and Nlrp3R258W mice produced comparable amounts of TNF-a
in response to the same stimuli (Figure 2A). Whereas stimulation
with both LPS and ATP was required to induce processing of
Figure 1. Cutaneous Inflammation in Nlrp3R258W Mice Requires MCs
(A) Linear bodyweight (BW) curves of wild-type (WT, n = 13) and Nlrp3R258W (n = 20) mice (left panel) and B6KitW-sh/W-sh (n = 10) and Nlrp3R258WKitW-sh/W-sh (n = 10)
mice (right panel). Error bars represent mean ± SEM.
(B) Amounts of IL-1b in serum of WT, Nlrp3R258W, B6 KitW-sh/W-sh, and Nlrp3R258WKitW-sh/W-sh mice.
(C) Spleen weight of WT, Nlrp3R258W, B6 KitW-sh/W-sh, and Nlrp3R258WKitW-sh/W-sh mice.
(D) Percentage of B6KitW-sh/W-sh andNlrp3R258WKitW-sh/W-shmice that developed skin disease in the neonatal period. Results are derived frommice depicted in (A).
(E) Skin-disease score in Nlrp3R258W and Nlrp3R258WKitW-sh/W-sh. Results are derived from mice depicted in (A). Error bar indicates mean ± SEM.
(F) H&E (HE) and toluidine blue (TB) staining of involved skin from Nlrp3R258W and comparable region of Nlrp3R258WKitW-sh/W-sh.
(G) Immunofluorescence staining of avidin-positive MCs (red) and IL-1b (green) of involved skin from Nlrp3R258W and comparable region from WT B6 and
Nlrp3R258WKitW-sh/W-sh. Merged images are also shown. Inset represents high magnification of avidin-positive MC producing IL-1b (yellow-orange color). Notice
autofluorescence of epidermis and hair follicle in WT and Nlrp3R258W mice. Scale bar represents 100 mm.
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MCs and Skin Inflammation Driven by Nlrp3 Mutationpro-caspase-1 into its active p20 subunit in wild-typeMCs, stim-
ulationwith LPSwas sufficient to activate caspase-1 inMCs from
Nlrp3R258W mice (Figure 2B). In addition, treatment with TNF-a
alone induced IL-1b secretion in MCs from Nlrp3R258W mice,
whereas both TNF-a and ATP were required to induce IL-1b
secretion inwild-typeMCs (Figure 2C). Collectively, these results
indicate that theNlrp3R258Wprotein is constitutively active inMCs
in that IL-1b production only requires a priming step.IL-1b Production by MCs Expressing the Nlrp3R258W
Mutation Is Important for Disease Development
in Neonatal Nlrp3R258W Mice
To determine whether IL-1b production is important for disease
development, we crossed heterozygous Nlrp3R258W mice with
Il1b/ mice to generate mice expressing the Nlrp3R258W muta-
tion in the presence and absence of IL-1b. Nlrp3R258Wmice lack-
ing IL-1b developed normally after birth and, unlike their Nlrp3Immunity 37, 85–95, July 27, 2012 ª2012 Elsevier Inc. 87
Figure 2. Priming with LPS or TNF-a Is Sufficient to Induce
Caspase-1 Activation and IL-1b Secretion in MCs Expressing the
Nlrp3R258W Mutation
(A) BMCMCs were incubated with LPS (100 ng/ml) for 15 hr and stimulated
with ATP (5 mM) or R837 (100 mM) for 30 min. IL-1b (left) and TNF-a (right) in
culture supernatants was measured by ELISA.
(B) Immunoblot analysis of extracts of cells together with cell supernatant of
BMCMCs from Nlrp3R258W and wild-type (WT) mice. Cells were incubated with
LPS (100 ng/ml) for 4 hr and then stimulated by ATP (5 mM) or left untreated.
(C) BMCMCswere pretreatedwith TNF-a (100 ng/ml or 300ng/ml) for 24 hr and
stimulated with ATP (5 mM) for 30 min. IL-1b in culture supernatants were
measured by ELISA. Error bars represent mean ± SD. Significance was
determined by two-tailed Student’s t test; *p < 0.05. Data shown are repre-
sentative of three independent experiments.
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MCs and Skin Inflammation Driven by Nlrp3 Mutationmutant littermates, they gained weight and did not develop skin
disease (Figures 3A and 3B). To determine whether IL-1b
production by MCs is important for disease development, we
adoptively transferred BMCMCs from wild-type, Nlrp3R258W, or
Nlrp3R258WIl1b/ mice into the skin of B6-KitW-sh/W-sh or
Nlrp3R258WKitW-sh/W-sh mice at postneonatal day 1 (PND 1).
MC-deficient recipient mice were reconstituted with wild-type
or mutant MCs in the skin of the posterior collar area, where
disease develops in 100% of neonatal Nlrp3R258W mice.
Neonatal B6-KitW-sh/W-sh mice reconstituted with MCs from
wild-type, Nlrp3R258W, or Nlrp3R258WIl1b/ mice contained
3- to 4-fold more MCs than their B6-KitW-sh/W-sh littermates88 Immunity 37, 85–95, July 27, 2012 ª2012 Elsevier Inc.and 40% of conventional-type MCs present in the same
skin area of age-matched wild-type or Nlrp3R258W mice (Fig-
ure S3). Notably, Nlrp3R258WKitW-sh/W-sh recipient mice adop-
tively transferred with MCs from Nlrp3R258W mice, but not from
Nlrp3R258WIl1b/ or wild-type mice, developed inflammatory
skin disease at the site of MC reconstitution that was compa-
rable to that observed in nonmanipulated Nlrp3R258W mice (Fig-
ure 3C; Figure S3E). Disease development was associated with
reduced body weight (Figure 3D) and production of IL-1b in the
skin (Figure 3E). Notably, adoptive transfer of MCs from
Nlrp3R258W mice into B6-KitW-sh/W-sh mice did not induce skin
disease (Figures 3C and 3E). These results indicate that MCs ex-
pressing the Nlrp3R258W mutation and IL-1b are important for
disease, but also suggest that another cell harboring the
Nlrp3R258W mutation is also required for disease development.
Depletion of the Microbiota Inhibits Disease
Development in Nlrp3R258W Mice
The skin lesions observed in newborn Nlrp3R258W mice devel-
oped in limited areas such as the posterior collar area and peria-
nal region (Figure S1), suggesting that environmental stimuli may
play a role in triggering cutaneous disease. Because microbial
TLR ligands such as LPS are necessary and sufficient to induce
robust IL-1b production inMCs expressing the Nlrp3R258Wmuta-
tion (Figure 2A), we examined whether depletion of commensal
bacteria with antibiotics could alter the development of skin
disease. Newborn mice are colonized soon after birth by
commensal bacteria derived from their mother (Hasegawa
et al., 2010). Therefore, we treated pregnant female Nlrp3R258W
mice with a cocktail of antibiotics in the drinking water for
2 weeks, beginning 2 days prior to giving birth. This antibiotic
treatment resulted in 4-log depletion of culturable bacteria in
the oral cavity of nursing mothers and 3-log depletion in the
skin of newborn mice (Figure 4A). Furthermore, antibiotic treat-
ment resulted in robust reduction of skin bacteria in neonatal
mice as assessed by quantitative PCR of eubacteria 16S ribo-
somal RNA (rRNA) DNA (Figure 4B) and did not alter the number
of MCs in the skin (Figure S3). Importantly, treatment with antibi-
otics led to reduced disease incidence and score compared to
untreated Nlrp3R258W mice (Figure 4C; Figure S4). Furthermore,
antibiotic-treated Nlrp3R258W mice had less weight loss (Fig-
ure 4D) and splenomegaly (Figure 4E) than their untreated litter-
mates. Furthermore, administration of antibiotics led to reduced
amounts of IL-1b in the serum and skin of Nlrp3R258W mice
compared to untreated Nlrp3R258W mice (Figures 4F and 4G).
Notably, antibiotic treatment also reduced the amounts of
TNF-a in the skin of both wild-type and Nlrp3R258W littermates
(Figure 4G). However, the production of TNF-a was comparable
in the skin of untreated wild-type and Nlrp3R258W littermates (Fig-
ure 4G). If themicrobiota induces TNF-a to trigger skin disease in
neonatal Nlrp3R258W mice, administration of TNF-a or induced
release of endogenous TNF-a release would be expected to
trigger skin disease in antibiotic-treated Nlrp3R258W mice.
Notably, intradermal administration of compound 48/80, a mole-
cule that induces the release of TNF-a, and other molecules from
connective-tissue-type MC secretory granules (Mousli et al.,
1990) or intradermal injection of recombinant (r) TNF-a induced
skin disease (Figure 4H) and IL-1b production (Figure 4I) in anti-
biotic-treated Nlrp3R258W mice, but not in wild-type littermates.
Figure 3. IL-1bProduction byMCsExpress-
ing the Nlrp3R258W Mutation Is Important for
Skin Disease in Nlrp3R258W Mice
(A) Linear growth curve of Nlrp3R258WIl1b/ (n = 6)
and Il1b/ littermates (n = 8).
(B) Skin-disease score from 2-week-old
Nlrp3R258W and Nlrp3R258WIl1b/ mice. Dots
represent individual mice. Bar represents mean
values. ***p < 0.001.
(C) Skin-disease score in Nlrp3R258W,
Nlrp3R258WKitW-sh/W-sh, and indicated recipient
mice reconstituted in the skin with MCs from
indicated mice at PND 1. Dots represent individual
mice. Bar represents mean values.
(D) Percentage of weight loss of Nlrp3R258W
KitW-sh/W-sh mice and Nlrp3R258WKitW-sh/W-sh mice
reconstituted with MCs from Nlrp3R258W mice at
PND 1. Results shown are from 2-week-old mice
and normalized to weight of control B6 KitW-sh/W-sh
littermates (WT). *p < 0.05. KI, knockin.
(E) IL-1b (left panel) and TNF-a (right panel) levels
in skin of Nlrp3R258W, Nlrp3R258WKitW-sh/W-sh, and
indicated recipient mice reconstituted in the skin
with MCs from indicated mice at PND 1. Results
are from 2-week-old mice. Bars represent mean
values.
Significance in (D) and (E) was determined by one-
way ANOVA; *p < 0.05, **p < 0.01, ***p < 0.001. NS,
not significant. Data shown are representative of
two independent experiments (C)–(E).
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MCs and Skin Inflammation Driven by Nlrp3 MutationThese results indicate that the indigenous microbiota contribute
to TNF-a and IL-1b production and the development of skin
disease in newborn Nlrp3R258W mice.
Neutralization of TNF-a Abrogates the Development
of Skin Disease in Neonatal Nlrp3R258W Mice
Because treatment with antibiotics reduced the amounts of
TNF-a in the skin, and TNF-a alone can induce IL-1b secretion
in MCs from Nlrp3R258W mice (Figures 4G and 2C), we tested
whether TNF-a plays a role in the development of skin disease
in newborn Nlrp3R258W mice. To assess this, we treated
Nlrp3R258Wmice at PND 1with TNF-a-blocking monoclonal anti-
body or isotype-matched control immunoglobulin G (IgG) intra-Immunity 37, 8peritoneally. Neutralization of TNF-a
abrogated the loss of body weight, the
development of skin disease, and spleno-
megaly in newborn Nlrp3R258W mice
(Figures 5A, 5B and 5C; Figure S5A).
Histological analysis revealed that admin-
istration of TNF-a antibody prevented
inflammatory skin disease in newborn
Nlrp3R258W mice (Figure 5D). Notably,
treatment with TNF-a antibody inhibited
the production of IL-1b in Nlrp3R258W
mice (Figure 5E). After weaning, cuta-
neous disease gradually disappeared
in Nlrp3R258W mice, but as previously
reported (Meng et al., 2009), a significant
number of adult Nlrp3R258W mice
relapsed at older age (>12 weeks) anddeveloped skin disease affecting the ears, the top of the head,
and the tail base region (Figure S5B). In contrast to neonatal
mice, treatment with TNF-a antibody did not inhibit ongoing
skin disease in adult Nlrp3R258W mice (Figure 5F). Collectively,
these results indicate that TNF-a is critical for the development
of disease in neonatal mice, but its inhibition does not improve
disease in adult Nlrp3R258W mice.
MC-Intrinsic TNF-a, but Not IL-1b, Is Critical for Skin
Disease Induced by Compound 48/40 in Adult
Nlrp3R258W Mice
TNF-a is a key cytokine that is stored in the granules of MCs
(Echtenacher et al., 1996; Gordon and Galli, 1990; Maurer5–95, July 27, 2012 ª2012 Elsevier Inc. 89
Figure 4. Depletion of the Microbiota Inhibits Disease Development in Nlrp3R258W Mice
(A) Number of culturable bacteria in the oral cavity of nursing female mice (left panel) and skin (posterior collar region) of newborn mice (right panel) in untreated
(Untreat) and antibiotic-treated (Abx) mice. Results are mean ± SD (n = 5).
(B) Normalized 16S rRNA gene analysis of the skin from untreated and Abx-treated mice.
(C) Skin-disease score in untreated and Abx-treated 2-week-old Nlrp3R258W mice. Dots represent individual mice. Bar represents mean values.
(D) Percentage of weight loss in untreated and Abx-treated 2-week-old Nlrp3R258W mice. Results shown are normalized to weight of control B6 littermates (WT).
*p < 0.05. KI, knockin.
(E) Spleen weight of untreated and Abx-treated 2-week-old Nlrp3R258W mice and WT mice.
(F) and (G) IL-1b in serum (F) and skin (G, top panel) and TNF-a in skin (G, bottom panel) of untreated and Abx-treated 2-week-old Nlrp3R258W mice and wild-type
littermates. Each dot represents an individual mouse. Horizontal bars indicate mean values.
(H) and (I) Skin-disease score (H) and skin IL-1b (I) in untreated and Abx-treated 2-week-old Nlrp3R258W mice induced by compound 48/80 or TNF-a intradermal
injection. Dots represent individual mice. Bar represents mean values. (I) *p < 0.05, **p < 0.01, ***p < 0.001. Data shown are representative of two independent
experiments.
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Figure 5. Neutralization of TNF-aAbrogates
the Development of Skin Disease in
Neonatal Nlrp3R258W Mice
(A) Percentage of weight loss in untreated and
Nlrp3R258W mice treated with TNF-a antibody or
control antibody at PND 1. Results shown are from
2-week-old mice normalized to the weight of
control B6 littermates (WT). *p < 0.05. KI, knockin.
(B) Spleen weight of 2-week-old untreated mice
and antibody-treated Nlrp3R258W and WT litter-
mates. Mice were treated with control or TNF-a
antibody at PND 1. *p < 0.05. NS, not significant.
(C) Skin-disease score in 2-week-old untreated
and antibody-treated Nlrp3R258W littermates. Mice
were treated with control or TNF-a antibody at
PND 1. Dots represent individual mice. Bar
represents mean values. ***p < 0.001. NS, not
significant.
(D) Representative H&E staining of skin from
2-week-old untreated WT and Nlrp3R258W litter-
mates and a littermate treated with TNF-a anti-
body.
(E) Serum IL-1b (left panel) and TNF-a (right panel)
levels in 2-week-old untreated WT and Nlrp3R258W
mice and antibody-treated littermates. Mice were
treated with control or TNF-a antibody at PND 1.
(F) Skin-disease score in adult untreated and
antibody-treated Nlrp3R258W mice. Mice were
treated with TNF-a antibody twice weekly. Hori-
zontal bars indicate mean values. Dots represent
individual mice. NS, not significant. Data shown
are representative of three (A–D) and two (E and F)
independent experiments.
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MCs and Skin Inflammation Driven by Nlrp3 Mutationet al., 2006; Suto et al., 2006). Therefore, we hypothesized
that granule-associated TNF-a within MCs may be important
in triggering skin disease in Nlrp3R258W mice. To test
this, we injected compound 48/80 into the uninvolved skin of
wild-type, Nlrp3R258W, and Nlrp3R258WKitW-sh/W-sh adult mice
and assessed disease and IL-1b production in the skin. Admin-
istration of compound 48/80 induced marked neutrophilic
inflammation in the skin and IL-1b cytokine production at the
injection site in Nlrp3R258W mice, but not in wild-type or
Nlrp3R258WKitW-sh/W-sh mice (Figures 6A and 6B; Figure S6). To
determine whether TNF-a and/or IL-1b produced by MCs is
important for inducing skin inflammation in Nlrp3R258W mice,
we adoptively transferred BMCMCs from wild-type, Tnfa/,
and Il1b/ mice into the skin of adult Nlrp3R258WKitW-sh/W-sh
mice. MC-deficient Nlrp3R258WKitW-sh/W-sh mice reconstituted
with MCs from wild-type, but not Tnfa/ mice, developed
neutrophilic skin inflammation and increased IL-1b production
upon administration of compound 48/80 at the site of injection
(Figures 6A and 6B). Notably, reconstitution with BMCMCs
from Il1b/ mice induced inflammation and IL-1b production
(Figures 6A and 6B). These results indicate that TNF-a from
MCs can induce IL-1b production and inflammatory skin disease
in Nlrp3R258W mice. Furthermore, MC-intrinsic IL-1b is not
required for 48/80-induced skin disease and IL-1b production
in adult Nlrp3R258W mice.Administration of TNF-a Induces IL-1b-Dependent Skin
Inflammation in Adult Nlrp3R258W Mice
We next asked whether TNF-a is sufficient to induce skin inflam-
mation via IL-1b in adult Nlrp3R258W mice. To test this, we first
injected rTNF-a into the skin of the ear pinna of disease-
free adult Nlrp3R258W and wild-type mice. Administration of
rTNF-a induced marked thickening and redness in the skin of
Nlrp3R258W B6 mice, but not wild-type mice (Figure S7). Further-
more, skin disease induced by rTNF-a was reduced in
Nlrp3R258WKitW-sh/W-sh and abrogated in Nlrp3R258Wmice lacking
IL-1b (Figure S7). Histological examination revealed marked
neutrophil infiltration in the dermis of Nlrp3R258W mice injected
with rTNF-a, which was abolished in Nlrp3R258WIl1b/ mice
(Figure 7A). Consistent with these findings, the amounts of
IL-1b in the skin of Nlrp3R258W increased at the site of TNF-a
administration, and this was also observed in Nlrp3R258W
KitW-sh/W-sh mice (Figure 7B). Taken together, these results indi-
cate that TNF-a can trigger skin inflammation via IL-1b in adult
Nlrp3R258W mice and that this is largely independent of MCs.
DISCUSSION
CAPS-associated missense NLRP3 mutations result in
enhanced activation of caspase-1 and secretion of IL-1b, leading
to inflammatory disease in the skin and other organs. However,Immunity 37, 85–95, July 27, 2012 ª2012 Elsevier Inc. 91
Figure 6. TNF-a Produced by MCs Can Induce Skin Disease in
Nlrp3R258W Mice
(A) Adult Nlrp3R258W, B6 (WT), KitW-sh/W-sh, and Nlrp3R258WKitW-sh/W-sh mice
reconstituted with MCs from WT, Tnfa/, and Il1b/ mice. Mice were intra-
dermally injected with compound 48/80 at the site of reconstitution. Repre-
sentative images of low power histology (LPH) and high power histology (HPH)
of H&E stained skin are shown. Bar indicates 100 mm.
(B) IL-1b levels in skin of wild-type (WT), Nlrp3R258WKitW-sh/W-sh, and
Nlrp3R258WKitW-sh/W-sh mice reconstituted with MCs from WT, Tnfa/, and
Il1b/mice.Mice were injected intradermally with compound 48/80 at the site
of MC reconstitution. Bars represent mean values. Significance was deter-
mined by one-way ANOVA; *p < 0.05. NS, not significant. Data shown are
representative of two independent experiments.
Figure 7. TNF-a Administration Induces IL-1b-Dependent Skin
Inflammation in Nlrp3R258W Mice
(A) Adult Nlrp3R258W, B6 (WT), Nlrp3R258WIl1b/, Nlrp3R258WKitW-sh/W-sh, and
B6-KitW-sh/W-sh mice were injected intradermally with TNF-a or PBS in the ear
pinna. Representative images of low power histology (LPH) and high power
histology (HPH) of H&E stained skin 48 hr after injection are shown. Bar indi-
cates 100 mm.
(B) IL-1b levels in the skin of indicated mice injected intradermally with PBS or
TNF-a in the ear pinna. Results shown are from 48 hr after injection. Bars
represent mean values. Significance was determined by one-way ANOVA;
**p < 0.01. NS, not significant. Data shown are representative of two inde-
pendent experiments.
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MCs and Skin Inflammation Driven by Nlrp3 Mutationthe cells and themechanism that orchestrate NLRP3-dependent
IL-1b-driven inflammatory disease in vivo remain unclear. We
show here that MCs play a critical role in the initiation of skin
inflammation and systemic disease in neonatal Nlrp3R258W
mice. Reconstitution experiments revealed that production of
IL-1b by MCs expressing the Nlrp3 mutation was important for
skin disease and delayed growth in neonatal mutant mice. Our
studies suggest that colonization of newborn mice by the micro-
biota induces local production of TNF-a, which primes MCs to
elicit dysregulated production of IL-1b, causing skin and
systemic disease. This model is consistent with the observation
that MCs expressing the Nlrp3R258Wmutation require stimulation
with TNF-a or LPS to secrete IL-1b. Unlike in normal cells, this
priming step is sufficient to trigger caspase-1 activation and
IL-1b secretion by inducing the expression of Nlrp3 and pro-
IL-1b (Bauernfeind et al., 2009; Franchi et al., 2009b). In our
Nlrp3R258W model, the microbiota are critical to induce IL-
1b-driven disease in neonatal mice. There is evidence that envi-
ronmental factors may play a role in triggering CAPS in humans.
For example, inflammatory episodes in FCAS are often induced
by exposure to cold, whereas NOMID patients are born healthy,
but they develop disease in early infancy. Thus, it is possible that
exposure to cold, which induces cytokines or other proinflam-
matory molecules (Theoharides et al., 2004; Zhu et al., 1996),92 Immunity 37, 85–95, July 27, 2012 ª2012 Elsevier Inc.can prime MCs to elicit IL-1b-driven disease. Similarly, coloniza-
tion by microbes could trigger inflammatory disease in NOMID
patients. Clearly, further work is needed to understand how envi-
ronmental factors contribute to the pathogenesis of CAPS in
humans.
MCs are widely distributed throughout the body; they are
located near epithelial surfaces such as the skin and airways
that are normally exposed to environmental cues (Galli et al.,
2008). Unlike macrophages, MCs can secrete a wide array of
granule-associated, preformed biologically active products,
including TNF-a, in response to a variety of stimuli, including
microbes (Gordon and Galli, 1990). Hence, exposure to micro-
bial products from commensal organisms could induce exocy-
tosis of MCs and secretion of TNF-a to prime mutant MCs for
IL-1b production in an autocrine and paracrine manner. Alterna-
tively, newly synthesized TNF-a derived from stimulation of MCs
by microbial molecules could mediate priming of MCs. Consis-
tent with the former model, administration of 48/80, a compound
that induces MC exocytosis, triggered IL-1b production and
neutrophilic inflammation in the skin of Nlrp3R258W mice, but
not in Nlrp3R258W mice deficient in MCs or in wild-type mice.
Furthermore, reconstitution of MC-deficient Nlrp3R258W mice
with MCs from wild-type mice, but not Tnfa/ mice, induced
IL-1b production and skin inflammation at the site of compound
Immunity
MCs and Skin Inflammation Driven by Nlrp3 Mutation48/80 administration. Other key findings also support an impor-
tant role for TNF-a in initiating skin disease in Nlrp3R258W mice.
First, neutralization of endogenous TNF-a abrogated the devel-
opment of skin disease. Second, intradermal injection of TNF-a
triggered local IL-1b production and inflammatory skin disease,
which was blocked in the absence of IL-1b, specifically in adult
Nlrp3R258W mice. In adult Nlrp3R258W mice, IL-1b production
induced by administration of TNF-a was undisturbed in the
absence of MCs. Similarly, MC-intrinsic IL-1b production was
dispensable for skin disease triggered by intradermal adminis-
tration of compound 48/80 into adult Nlrp3R258W mice. Thus,
IL-1b from a cell source other than MCs is important for skin
disease induced by 48/80 or rTNF administration in Nlrp3R258W
mice. In these adult-mouse models, MC-derived TNF-a is likely
to act on an intermediary myeloid cell-type that is the source of
IL-1b to cause disease. A role for cells other than MCs in skin
disease is also supported by the finding that adoptive transfer
of MCs expressing the Nlrp3R258W mutation induced skin
disease in MC-deficient Nlrp3R258W KitW-sh/W-sh mice, but not in
B6-KitW-sh/W-sh mice. Collectively, the results indicate that resi-
dent MCs expressing CAPS-associated NLRP3 mutations
produce TNF-a locally upon exposure to commensals, leading
to IL-1b secretion, which in turn primes additional innate immune
cells expressing the NLRP3 mutation to amplify local IL-1b
production and inflammatory disease. Although production of
both TNF-a and IL-1b by MCs is important for inducing disease
in the neonatal model, MC-independent production of IL-1b
appears to be critical for disease in adult Nlrp3R258W mice.
Although additional studies are needed to identify the cell(s)
involved, it is likely that macrophages, dendritic cells, or neutro-
phils expressing mutant Nlrp3 could contribute to IL-1b produc-
tion and the development of disease.
Activation of the Nlrp3 inflammasome leads not only to IL-1b
secretion, but also to production of IL-18, whose maturation is
mediated by caspase-1 (Arend et al., 2008). In addition, mono-
cytes from CAPS patients carrying disease-associated NLRP3
mutations exhibit enhanced pyroptosis after stimulation with
LPS (Fujisawa et al., 2007; Willingham et al., 2007). Therefore,
it is possible that activities other than those induced via IL-1b
contribute to inflammatory disease in CAPS patients. Consistent
with this possibility, genetic deletion of IL-1 signaling was asso-
ciated with marked improvement, but it did not abrogate disease
in mice harboring the disease-associated A350V or L351P Nlrp3
mutations (Brydges et al., 2009). In contrast, we found that dele-
tion of IL-1b in Nlrp3R258W mice fully rescued the mutant mice
from disease. In mice, the A350V or L351P Nlrp3 mutations
confer a more severe phenotype than the R258W mutation,
and this could explain, at least in part, the difference in results
(Brydges et al., 2009; Meng et al., 2009). In the last decade, bio-
logical inhibitors of IL-1 signaling or IL-1b antibodies have
become the most effective treatments for CAPS patients (Gold-
bach-Mansky et al., 2006; Hoffman et al., 2008; Lachmann et al.,
2009). In contrast, anti-TNF-a treatment had some positive
effects; however, its efficacy was very limited compared to
anti-IL-1b therapies (Ebrahimi-Fakhari et al., 2010; Federico
et al., 2003; Gunduz et al., 2008; Kallinich et al., 2005; Matsubara
et al., 2006). In accordance with the human studies, neutraliza-
tion of IL-1b with antibody was very effective in reducing inflam-
matory disease in adult Nlrp3R258W mice (Meng et al., 2009). Incontrast, TNF-a-blocking antibody abrogated the development
of disease in neonatal Nlrp3R258W mice, whereas it was ineffec-
tive in reducing ongoing disease in adult Nlrp3R258W mice, which
is consistent with studies in CAPS patients. These results
suggest that TNF-a is important in the initiation phase of the
disease, but it plays a minimal or no role at the later phases of
the disease. Although further work is needed to understand the
role of TNF-a in the pathogenesis of CAPS, one possibility is
that TNF-a is critical for the initial induction of pathogenic
IL-1b. Once IL-1b is produced, MCs and other IL-1b-producing
cells expressing mutant Nlrp3 can rely on IL-1b for priming and
eliciting IL-1b-driven inflammatory disease. The latter could
explain why therapies targeting IL-1b are very effective in treat-
ing CAPS patients with disease, whereas anti-TNF-a blockade
is not. In addition to CAPS, another IL-1b-driven autoinflamma-
tory disease, familial Mediterranean fever (FMF), is associated
with excess production of IL-1b through NLRP3-independent
activation of caspase-1 (Chae et al., 2006; Papin et al., 2007).
A recent study demonstrated that FMF-associated pyrin mutant
mice also developed skin inflammation at as early as 1 week of
age and suffered from severe inflammation in multiple tissues
(Chae et al., 2011). Because the time course and disease pheno-
type of pyrin mutant mice are similar to those of Nlrp3 mutant
mice, it is possible that MC-mediated mechanisms observed in
Nlrp3R258W mice also contribute to the development of disease




Nlrp3R258W mice have been described (Meng et al., 2009). C57BL/6, C57BL/
6-KitW-sh/W-sh (B6.CG-KitW-sh/HNihrJaeBsmJ), and Tnfa/ (B6.129S6-
Tnftm1Gkl/J) mice were purchased from Jackson Laboratories (Bar Harbor,
ME, USA). B6 Il1b/mice were originally obtained from Y. Iwakura (University
of Tokyo, Tokyo). All strains were housed under pathogen-free conditions. The
animal studies were conducted under approved protocols by the University of
Michigan Committee on Use and Care of Animals.
Preparation and Adoptive Transfer of Mast Cells
The preparation of BMCMCs was previously described (Yamada et al., 2003).
The purity of MCs was > 95% based on toluidine blue staining and surface
expression of CD117 and FcεR.
Adoptive transfer of MCs into MC-deficient KitW-sh/W-sh mice was performed
as described (Grimbaldeston et al., 2005). Briefly, BMCMCs were obtained
after a 4–5 week culture of bone marrow cells in medium containing
20 ng/ml recombinant mouse IL-3 (R&D Systems). For MC-reconstitution
studies, BMCMCs were adoptively transferred via intradermal injection of
2 3 106 cells in 40 ml PBS into the ear pinna (at 4–8 weeks old) or posterior
collar area (at PND 1) of MC-deficient recipient mice. Mice were evaluated
at 2–3 weeks (neonatal mice) or 4–5 weeks (adult mice) after intradermal trans-
fer of BMCMCs.
Administration of TNF-a Antibody and Antibiotics
Anti-TNF-a-blocking IgG (rat clone; MPG-XT3) was a gift from T. Moore
(University of Michigan). Newborn mice were given 60 mg in 30 ml of TNF-a anti-
body or isotype-matched control rat IgG (Sigma-Aldrich), intraperitoneally.
Adult Nlrp3R258W mice were treated with 500 mg of TNF-a antibody intraperito-
neally, weekly for 2 weeks. For antibiotic treatment, pregnant mice received an
antibiotic cocktail (1 g/L of ampicillin, 0.5 g/L of vancomycin, 1 g/L of metroni-
dazole, and 1 g/L of neomycin) in the drinking water 2 days before delivery, and
the treatment continued for 2 weeks. Newborn mice were given 50 mg in 40 ml
of rTNF-a at PND 3 or 1 mg in 40 ml of compound 48/80 at PND 3 and PND 6,Immunity 37, 85–95, July 27, 2012 ª2012 Elsevier Inc. 93
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newborns’ skin through collection and homogenization of tissue in sterile PBS.
The number of bacteria was determined by serial dilution of tissue samples,
followed by serial plating on brain-heart infusion broth for 48 hr at 37C under
aerobic conditions.
Skin-Disease Score
The severity of skin disease was evaluated using amodified skin-index scoring
system (Matsuda et al., 1997). Briefly, skin inflammation was evaluated every
other day as a cumulative score. The total disease-severity score from three
areas (head and neck, body, and perianal region) was defined as the sum of
the individual scores, graded as 0 (none), 1 (mild), 2 (moderate), and 3 (severe)
for each of four disease signs (erythema, alopecia, scales, and erosions). The
maximum score was 36.
Intradermal Injection
Adult mice (6–12 weeks old) were given compound 48/80 (1 mg in 20 ml per ear
pinna; Sigma-Aldrich), rTNF-a (500 ng in 20 ml per ear pinna; PeproTech), or
control PBS via intradermal injection. Tissue samples were collected 48 hr
after injection for analysis.
Histology
Skin tissue was formalin fixed, paraffin embedded, and sectioned for
hematoxylin and eosin (H&E), toluidine blue, and safranin O staning. For immu-
nofluorescence staining, sections were subjected to labeling with anti-IL-1b
(Armenian Hamster clone B122; Leinco Technologies) followed by fluorescein
isothiocyanate-conjugated secondary antibodies and Texas red-Avidin
staining.
Immunoblotting
Cells were lysed together with the cell supernatant by the addition of 1%
NP-40 complete protease inhibitor cocktail (Roche) and 2 mM dithiothreitol.
Clarified lysates were resolved by SDS-PAGE and transferred to polyvinyli-
dene fluoride membranes by electroblotting. The rabbit anti-mouse cas-
pase-1 was a kind gift from P. Vandanabeele (Ghent University, Belgium).
Preparation of Skin Extracts
Skin tissue (5 3 5 mm area) was removed and homogenized as illustrated in
Figure S2A. The skin homogenates were centrifuged and supernatants were
collected for cytokine measurements by ELISA.
Cytokine Levels
Chemokines and cytokines were measured with ELISA kits (R&D Systems).
Statistical Analysis
Most of the data were compared by two-tailed t test with unequal variance
(GraphPad Prism). Analysis of data involving multiple comparisons was per-
formed by one-way ANOVA. The slope of two regression lines was compared
using GraphPad Prism. Differences were considered significant when p values
were less than 0.05.
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